The Conversation (0)
The Telegraph reported that Hikma Pharmaceuticals (LSE:HIK) gained over 45 percent this year and first-half results beat market expectations.
The Telegraph reported that Hikma Pharmaceuticals (LSE:HIK) gained over 45 percent this year and first-half results beat market expectations.
As quoted in the market news:
Hikma has enjoyed bumper sales in the US of a generic antibiotic called doxycycline, used to prevent malaria and other infections. That has resulted in full-year guidance being raised for the third time in four months. Hikma now expects total revenue to rise 20pc in 2013, up from 17pc previously.